Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US-2017266079-A1 · Sep 21, 2017 · US
T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
US2016367651A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016367651-A1 |
| Application number | US-201415026841-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 1, 2014 |
| Priority date | Oct 1, 2013 |
| Publication date | Dec 22, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A vaccine contains a long-chain peptide antigen having a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines or two to ten consecutive asparagines. The vaccine may be an anticancer vaccine, an antibacterial vaccine or an antiviral vaccine. The vaccine may be a peptide vaccine, a DNA vaccine, an mRNA vaccine or a dendritic cell vaccine.
First claim
Opening claim text (preview).
1 . A vaccine including a long chain peptide antigen having a plurality of epitopes in which each interepitope sequence is one selected from a group consisting of two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines and two to ten consecutive asparagines. 2 . The vaccine as claimed in claim 1 , which is one selected from a group consisting of anticancer vaccines, antibacterial vaccines and antiviral vaccines. 3 . The vaccine as claimed in claim 2 , which is one selected from a group consisting of peptide vaccines, DNA vaccines, mRNA vaccines and dendritic cell vaccines. 4 . The vaccine as claimed in claim 3 , wherein the interepitope sequence is one selected from a group consisting of four to eight consecutive tyrosines, four to eight consecutive glutamines and four to eight consecutive asparagines. 5 . The vaccine as claimed in claim 3 , wherein the interepitope sequence is one selected from a group consisting of six consecutive tyrosines, six consecutive glutamines and six consecutive asparagines. 6 . The vaccine as claimed in claim 4 , which is an anticancer vaccine and a peptide vaccine. 7 . The vaccine as claimed in claim 4 , which contains a plurality of long chain peptide antigens. 8 . A combination vaccine which contains the vaccine as claimed in claim 7 and a hydrophobized polysaccharide as a delivery system. 9 . The vaccine as claimed in claim 8 , wherein the hydrophobized polysaccharide is cholesterol-modified pullulan (CHP). 10 . A method of treating a patient in need thereof, comprising administering to the patient the vaccine of claim 9 . 11 . A method of treating a patient in need thereof, comprising administering to the patient the vaccine of claim 1 . 12 . The vaccine as claimed in claim 1 , which is one selected from a group consisting of peptide vaccines, DNA vaccines, mRNA vaccines and dendritic cell vaccines. 13 . The vaccine as claimed in claim 1 , wherein the interepitope sequence is one selected from a group consisting of four to eight consecutive tyrosines, four to eight consecutive glutamines and four to eight consecutive asparagines. 14 . The vaccine as claimed in claim 1 , wherein the interepitope sequence is one selected from a group consisting of six consecutive tyrosines, six consecutive glutamines and six consecutive asparagines. 15 . The vaccine as claimed in claim 1 , which is an anticancer vaccine and a peptide vaccine. 16 . The vaccine as claimed in claim 1 , which contains a plurality of long chain peptide antigens. 17 . A combination vaccine which contains the vaccine as claimed in claim 1 and a hydrophobized polysaccharide as a delivery system. 18 . The vaccine as claimed in claim 17 , wherein the hydrophobized polysaccharide is cholesterol-modified pullulan (CHP).
Assignees
Inventors
Classifications
Antivirals · CPC title
Antibacterial agents · CPC title
Antineoplastic agents · CPC title
Hemosporidia antigens, e.g. Plasmodium antigens · CPC title
Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016367651A1 cover?
- A vaccine contains a long-chain peptide antigen having a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains two to ten consecutive tyrosines, two to ten consecutive threonines, two to ten consecutive alanines, two to ten consecutive histidines, two to ten consecutive glutamines or two to ten consecutive asparagines. The vaccine may be an an…
- Who is the assignee on this patent?
- Univ Mie, Univ Kyoto
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0011. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Dec 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).